[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
February 16, 2011

Study: Few Advocacy Groups Disclose Grants From Drug Companies

JAMA. 2011;305(7):662. doi:10.1001/jama.2011.119

Influential disease-specific advocacy organizations that call for more research and access to treatment often do not disclose funding they receive from pharmaceutical companies that make the very medications they may encourage their members to use.

Researchers arrived at that conclusion after they analyzed $3.2 million in grants that Eli Lilly and Company of Indianapolis, Ind, gave to 161 health advocacy organizations in the first 2 quarters of 2007. Their findings showed that only 25% of the advocacy groups disclosed the Lilly grants on their Web sites and only 10% acknowledged Lilly as a grant event sponsor (Rothman SM et al. Am J Public Health. doi:10.2105/AJPH.2010.300027 [published online ahead of print January 13, 2011]). None of the organizations disclosed the specific grant amount they received.